|15th September 2020||Joel Lewis||5,171||Grant/award etc.||$2.93||$15,151.03|
|4th September 2020||Richard E Uihlein||10,000||Open or private purchase||$2.55||$25,500.00|
|4th September 2020||Kevin D Freeman||5,000||Open or private purchase||$2.57||$12,848.00|
|19th March 2020||Kevin D Freeman||6,000||Open or private purchase||$1.64||$9,844.20|
|13th February 2020||Richard E Uihlein||18,638||Exercise of derivative||$4.72||$87,971.36|
|13th February 2020||Richard E Uihlein||46,875||Exercise of derivative||$2.39||$112,031.25|
|9th February 2020||Joel Lewis||8,000||Exercise of derivative||$2.39||$19,120.00|
|17th January 2020||Fund, L.P. 10 X||10,000||Open or private sale||$2.97||$29,700.00|
|9th January 2020||Joel Lewis||20,455||Grant/award etc.||$2.86||$58,501.30|
|9th January 2020||Richard E Uihlein||12,238||Grant/award etc.||$2.86||$35,000.68|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Galectin Therapeutics, Inc. engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.